The Goldman Sachs Group Issues Pessimistic Forecast for Danaher (NYSE:DHR) Stock Price

Danaher (NYSE:DHR) had its price target dropped by investment analysts at The Goldman Sachs Group from $270.00 to $265.00 in a report issued on Thursday,MarketScreener reports. The brokerage presently has a “buy” rating on the conglomerate’s stock. The Goldman Sachs Group’s target price indicates a potential upside of 21.11% from the company’s previous close.

Other analysts have also recently issued research reports about the company. Argus set a $265.00 target price on Danaher in a research report on Wednesday, January 14th. Jefferies Financial Group lifted their target price on shares of Danaher from $255.00 to $265.00 and gave the company a “buy” rating in a research note on Wednesday. Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a research report on Saturday, November 22nd. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Danaher in a research note on Thursday. Finally, Evercore ISI reissued an “outperform” rating and set a $254.00 price objective on shares of Danaher in a research report on Wednesday. Twenty equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $252.32.

Danaher Trading Down 0.4%

Danaher stock opened at $218.82 on Thursday. The firm has a market cap of $154.56 billion, a price-to-earnings ratio of 43.42, a price-to-earnings-growth ratio of 3.12 and a beta of 0.89. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.10 and a current ratio of 1.87. The firm’s 50 day moving average price is $230.60 and its two-hundred day moving average price is $213.96. Danaher has a 1 year low of $171.00 and a 1 year high of $242.80.

Danaher (NYSE:DHR) last announced its earnings results on Wednesday, January 28th. The conglomerate reported $2.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.14 by $0.09. The company had revenue of $6.84 billion for the quarter, compared to analyst estimates of $6.79 billion. Danaher had a return on equity of 10.81% and a net margin of 14.71%.Danaher’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.14 earnings per share. Danaher has set its FY 2026 guidance at 8.350-8.500 EPS. On average, research analysts predict that Danaher will post 7.63 EPS for the current fiscal year.

Insider Transactions at Danaher

In related news, SVP Georgeann Couchara sold 5,174 shares of the stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the completion of the sale, the senior vice president owned 2,625 shares in the company, valued at $552,352.50. This trade represents a 66.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Brian W. Ellis sold 21,776 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the sale, the senior vice president directly owned 14,553 shares of the company’s stock, valued at approximately $3,190,454.19. The trade was a 59.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 30,248 shares of company stock valued at $6,609,663. 11.10% of the stock is owned by insiders.

Institutional Trading of Danaher

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Sivia Capital Partners LLC boosted its holdings in Danaher by 6.3% in the second quarter. Sivia Capital Partners LLC now owns 2,009 shares of the conglomerate’s stock valued at $397,000 after acquiring an additional 119 shares during the last quarter. PFG Investments LLC raised its holdings in Danaher by 4.6% during the 2nd quarter. PFG Investments LLC now owns 5,233 shares of the conglomerate’s stock worth $1,034,000 after buying an additional 228 shares during the period. Robeco Institutional Asset Management B.V. raised its holdings in shares of Danaher by 161.2% during the second quarter. Robeco Institutional Asset Management B.V. now owns 175,724 shares of the conglomerate’s stock worth $34,713,000 after acquiring an additional 108,448 shares during the period. Naples Global Advisors LLC bought a new stake in shares of Danaher in the second quarter valued at about $270,000. Finally, Lecap Asset Management Ltd. raised its position in Danaher by 185.2% in the 2nd quarter. Lecap Asset Management Ltd. now owns 4,073 shares of the conglomerate’s stock valued at $805,000 after buying an additional 2,645 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

More Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Q4 results beat on EPS and management set FY2026 EPS guidance of $8.35–$8.50, which is above many street estimates and supports upside to earnings expectations. Danaher (DHR) Tops Q4 Earnings Estimates, Issues Solid 2026 Outlook
• Positive Sentiment: JPMorgan raised its price target to $275 and kept an overweight rating, signaling continued bullish sentiment among some large sell‑side shops. Benzinga
• Positive Sentiment: Molecular Devices (a Danaher business) announced a partnership to expand automated, AI‑ready research solutions — a product/market development that supports longer‑term growth in lab automation and software‑enabled sales. Molecular Devices Expands Access to Automated, AI-Ready Research Solutions
• Neutral Sentiment: Goldman Sachs trimmed its target slightly to $265 but maintained a buy rating, a modest calibration that still implies material upside but signals some caution. MarketScreener
• Neutral Sentiment: Earnings call transcripts and highlights show management emphasizing free cash flow and balance sheet strength, but a cautious tone on near‑term demand. These details provide context but are not unambiguously positive or negative. Danaher (DHR) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Market commentary and headlines framed the report as “in‑line” on sales and cautioned investors that the post‑earnings dip may not be a good buying opportunity, which likely amplified selling pressure. Danaher Stock Plunge Does Not Represent A Good Entry Point
• Negative Sentiment: Despite the EPS beat, some outlets highlighted the stock drop after an essentially in‑line revenue/outlook, reinforcing bearish sentiment in the short term. Danaher drops after in-line earnings outlook
• Negative Sentiment: Valuation is elevated (P/E ~43) versus historical averages, which can make the stock more sensitive to any guidance softness or mixed indicators.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.